WHO Recommends nPOC-NAAT & Tongue Swabs for TB Diagnosis; India's NTEP Deploys AI-Enabled Portable X-Rays

RK-251: India's ROS-Activated Smart Cancer Drug Could Transform Chemotherapy

RK-251 is a novel 'smart' cancer drug developed by Indian researchers that activates only inside cancer cells using high reactive oxygen species (ROS) levels, potentially reducing chemotherapy side effects. This marks a significant advancement in targeted cancer therapy and is a key topic for UPSC Science & Technology.

Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

A new proposal suggests creating a Patient Data Collective (PDC) for rare diseases in India, modeled on the Amul dairy cooperative. This collective would pool patient data to accelerate drug discovery and clinical trials, addressing the challenge of small patient populations for rare diseases.

Private Industry Accounts for 51.8% of India's R&D Spending; ANRF Corpus ₹50,000 Cr

India's private sector has overtaken the government in R&D spending for the first time, accounting for 51.8% in 2023-24. However, part of the surge is due to better data capture. India's R&D intensity remains low at 0.84% of GDP. The Anusandhan National Research Foundation (₹50,000 crore) aims to boost private sector research and deepen the research workforce.

WHO's IARC Classifies Hydrochlorothiazide, Voriconazole, Tacrolimus as Group 1 Carcinogens

Three widely used medicines for hypertension, fungal infections, and transplant rejection have been classified as Group 1 carcinogens by WHO's IARC. Patients are warned not to discontinue treatment without consulting doctors, as the classification identifies hazard, not real-world risk at prescribed doses.

VP Launches India Valve Registry for Heart Valve Disease Research; TN Reports 2,590 Valve Replacements in 20 Months

The Vice-President launched the India Valve Registry, a first-of-its-kind clinician-led platform to collect real-world data on valvular heart disease and interventions in India. The registry will generate India-specific evidence to improve patient care, while Tamil Nadu's CMCHIS data reveals 2,590 valve replacements in 20 months, highlighting the burden of rheumatic heart disease and the success of state-led healthcare.

Stem Cell Therapy for Autism Restricted to Clinical Trials; Health Ministry Advisory Follows SC Order

The Union Health Ministry has reiterated that stem cell therapy for Autism Spectrum Disorder (ASD) can only be offered as part of approved clinical trials, not as routine or commercial treatment. This follows a landmark Supreme Court judgment in January 2026 that examined the issue. The advisory reinforces existing regulations under the Clinical Establishments Act, 2010, and the National Guidelines for Stem Cell Research, 2017.

SC Applies Section 498A to Live-in Relationships; NOTTO Launches Real-Time Organ Transplant Portal with Aadhaar Pledges

The Indian Express UPSC Key for August 4, 2026, covers multiple crucial topics: the Supreme Court's ruling extending Section 498A cruelty protection to live-in relationships, the launch of a real-time organ transplant portal by NOTTO, the Vikram Sarabhai Medal awarded to Annapurni Subramaniam, India's resilient fertiliser supply amid the Iran war, the science behind Europe's wildfires, and the Ceuta migrant crisis. These topics span Polity, Health, Science, Environment, and International Relations, offering direct material for UPSC Prelims and Mains.

IIT Kharagpur Applies for MD, IIT Madras Plans MBBS: IITs, IISc Redefine Medical Education

India's premier engineering institutes (IITs, IISc) are entering medical education, signaling a paradigm shift under NEP 2020. IIT Kharagpur applied for MD (March 2026), IIT Madras plans MBBS, and IISc's Tata Medical School will offer MD-PhD from 2027. This convergence aims to create 'physician-scientists' and reduce medical device imports, but faces regulatory and capital challenges.